Xia Lei, Ding Shichao, Wang Xuezhen, Zhang Xiaoyu, Zhu Lin, Zhang Hairong, Li Huirong
Department of Pathology, Shandong University of Traditional Chinese Medicine, Jinan, China.
Department of Internal Medicine, The Third Affiliated Hospital of Shandong First Medical University, Jinan, China.
Front Pharmacol. 2023 Jan 4;13:1048484. doi: 10.3389/fphar.2022.1048484. eCollection 2022.
New anti-cancer drugs are constantly being developed, especially targeted drugs. Although these drugs have achieved significant clinical efficacy, they do not play a significant role in ovarian cancer. Moreover, the research cycle and costs of such drugs are often huge. The repositioning of conventional drugs has gradually become a concern. Statins, as traditional lipid-lowering drugs, play a role mainly by inhibiting HMGCR. In recent years, epidemiological studies and experiments have confirmed its anti-cancer effect, especially the effect of anti-ovarian cancer. The mutation rate of TP53 in ovarian cancer is as high as 95%, while HMGCR is often highly expressed in TP53 mutant tumors. However, the effect of prospective clinical trials is not ideal. This result seems understandable considering that it seems unrealistic for a lipid-lowering drug to completely inhibit tumor growth. Therefore, statins play more synergistic roles in the treatment of ovarian cancer. Because ovarian cancer is a highly heterogeneous tumor, it may be a good choice to deeply understand the mechanism of statins in the treatment of ovarian cancer and achieve precise treatment by combining it with other drugs.
新型抗癌药物不断研发，尤其是靶向药物。尽管这些药物已取得显著临床疗效，但在卵巢癌治疗中作用不显著。此外，此类药物的研究周期和成本往往巨大。传统药物的重新定位逐渐受到关注。他汀类药物作为传统降脂药，主要通过抑制HMGCR发挥作用。近年来，流行病学研究和实验证实了其抗癌作用，尤其是抗卵巢癌作用。卵巢癌中TP53的突变率高达95%，而HMGCR在TP53突变肿瘤中常高表达。然而，前瞻性临床试验效果并不理想。考虑到一种降脂药要完全抑制肿瘤生长似乎不现实，这个结果似乎可以理解。因此，他汀类药物在卵巢癌治疗中更多地发挥协同作用。由于卵巢癌是一种高度异质性肿瘤，深入了解他汀类药物治疗卵巢癌的机制并将其与其他药物联合实现精准治疗可能是个不错的选择。
Zotero 插件
